<!doctype html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta content="width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no" name="viewport">
  <meta name="format-detection" content="telephone=no">

 <!-- <META HTTP-EQUIV="pragma" CONTENT="no-cache">
  <META HTTP-EQUIV="Cache-Control" CONTENT="no-cache, must-revalidate">
  <META HTTP-EQUIV="expires" CONTENT="0">-->
  
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<link rel="shortcut icon" href="https://www.qimingvc.com/sites/default/files/favicon_1.ico" type="image/vnd.microsoft.icon" />
<meta name="description" content="Qiming Venture Partners is a top-tier VC firm with outstanding reputation. With our exceptional investment performances, we have been widely recognized by investors from around the world.We have a reputation for being entrepreneur friendly." />
<meta name="keywords" content="qiming ventures, qiming venture partners, qiming, healthcare, 启明创投, 启明, 风险投资, TMT, 医疗健康" />
<meta name="robots" content="follow, index" />
<meta name="generator" content="TUYI (http://www.tuyidesign.com)" />
<link rel="image_src" href="http://www.qimingvc.com/sites/all/themes/qiming/images/logo.svg" />
<link rel="canonical" href="https://www.qimingvc.com/en/node/2870/http%3A/sites/all/themes/qiming/images/logo.svg" />
<link rel="shortlink" href="https://www.qimingvc.com/en/node/2870/http%3A/sites/all/themes/qiming/images/logo.svg" />
  <title>结核诊断技术新革命 | Qiming Venture Partners</title>
    <link type="text/css" rel="stylesheet" href="https://www.qimingvc.com/sites/default/files/css/css_xE-rWrJf-fncB6ztZfd2huxqgxu4WO-qwma6Xer30m4.css" media="all" />
<link type="text/css" rel="stylesheet" href="https://www.qimingvc.com/sites/default/files/css/css_WkA3l5PABYsmAT6RuP_eKPA5CHBuLYSgAnfF-uTAwZI.css" media="all" />
<link type="text/css" rel="stylesheet" href="https://www.qimingvc.com/sites/default/files/css/css_W2kp5XFLy3cDWCei6IzZoAAfW7H3JLbjygEbhDg6HQ4.css" media="all" />
<link type="text/css" rel="stylesheet" href="https://www.qimingvc.com/sites/default/files/css/css_nfcPyOFO9FMlFbG4Nruw2C2q0-DxKGgPUF8w_nw-JF0.css" media="all" />

<!--[if lt IE 9]>
<link type="text/css" rel="stylesheet" href="https://www.qimingvc.com/sites/all/themes/qiming/css/ie.css?t5ags3" media="all" />
<![endif]-->
<link type="text/css" rel="stylesheet" href="https://www.qimingvc.com/sites/default/files/css/css_6bbUhaD_i6j4vDXTbDZ-b2jKrvhk0SBLGDi4bC17XT4.css" media="all" />
</head>
<body class="html not-front not-logged-in no-sidebars page-node page-node- page-node-2870 page-node-http page-node-http-sites page-node-http-sites-all page-node-http-sites-all-themes page-node-http-sites-all-themes-qiming page-node-http-sites-all-themes-qiming-images page-node-http-sites-all-themes-qiming-images-logosvg node-type-news i18n-en en" >
    <!--<div class="open-screen">
    <video src="images/1.mp4" id="openScreenVideo" autoplay="autoplay" muted="muted"></video>
</div>-->

<div class="header">
    <div class="w clearfix">
                    <div class="logo">
                <a href="/en" title="Qiming Venture Partners" rel="home" id="logo">
                    <img src="/sites/all/themes/qiming/images/logo.svg"
                         alt="Qiming Venture Partners"/>
                </a>
            </div>
                <div class="nav-btn">
            <span></span>
        </div>
                    <div class="lang-box">
                    <div id="block-locale-language" class="block block-locale">

    
    <ul class="language-switcher-locale-url"><li class="zh-hans first"><a href="/cn/node/2870/http%3A/sites/all/themes/qiming/images/logo.svg" class="language-link" xml:lang="zh-hans">中</a></li>
<li class="en last active"><a href="/en/node/2870/http%3A/sites/all/themes/qiming/images/logo.svg" class="language-link active" xml:lang="en">EN</a></li>
</ul></div>
            </div>
        
                    <div class="nav">
                    <div id="block-system-main-menu" class="block block-system block-menu">

    
    <ul class="menu clearfix"><li class="first leaf"><a href="/en/team">Team</a></li>
<li class="leaf"><a href="/en/portfolio">Portfolio</a></li>
<li class="leaf"><a href="/en/insights">Insights</a></li>
<li class="leaf"><a href="/en/newsroom">Newsroom</a></li>
<li class="last leaf"><a href="/en/about">About Us</a></li>
</ul></div>
            </div>
            </div>
</div>
    <div class="node-wrapper">
        <div class="w">
                                                    <div class="tabs"></div>                                </div>
                        <div id="block-system-main" class="block block-system">

    
    <div class="news-detail news-detail-2870">
    <div class="w clearfix">
        <div class="news-detail-main">
            <!--            <div class="back" data-referer="--><!--"><a href="--><!--">&nbsp;</a></div>-->
            <div class="back"><a href="javascript:history.back();">&nbsp;</a></div>
            <div class="news-type">Portfolio News</div>

            <!--<a href="" class="news-type"></a>-->
            <h2 class="font-medium">结核诊断技术新革命</h2>
            <div class="news-source">
                  
          <span class="date-display-single">31/03/2015</span>    
                      |   
          启明创投    
                            </div>
            <div class="news-main">
                  
          <div><div class="news-group" readability="23"><p class="news002 rtecenter"><img height="395" src="/sites/default/files/images/news/QQ20150712203312.jpg" width="640" /></p><p align="justify" class="news004">TB-SAT: 判断感染结核杆菌新技术</p><p align="justify">&nbsp;&nbsp; &nbsp;&nbsp;</p><p align="justify">结核病是继艾滋病之后人类第二大杀手！根据世界卫生组织的统计，我国是全球22个结核病流行严重的国家之一，同时也是全球27个耐多药结核病流行严重的国家之一。由于缺乏有效疫苗，缺乏高特异性和敏感性诊断试剂，且耐药性结核病的不断涌现等原因，该病仍然是全球公共卫生的重大威胁。因此一种快速有效的诊断方法的诞生对于结核病的控制和传播是一场革命。</p><p align="justify">目前结核分枝杆菌诊断主要检测方法有结核菌素皮试、涂片、镜检、分枝杆菌培养、组织病理、结核抗体检测、结核PCR检测等。临床数据显示，不同检测方法对结核分枝杆菌感染的检出率均有一定效果。同时也发现，对于相同的送检标本组织，采用不同的检测方法会出现存在明显差异的检测结果。随着核酸扩增技术（NAAT）的不断发展，有力地推动了临床检验从宏观扩展到微观领域，从细胞水平深入到分子水平。</p><p align="justify" class="news004">TB-SAT与传统检测方法的比较</p><p align="justify" class="news004">&nbsp;</p><p align="center" class="news004"><img height="383" src="/sites/default/files/images/news/QQ20150712203316.png" width="640" /></p><p align="justify">目前我国对肺结核诊断主要依靠实验室诊断和临床体征相结合。实验室诊断主要包括涂片、培养法、免疫法、核酸扩增法如SAT等。使用最多的涂片和培养法在临床应用方面有着很多的不足。痰涂片虽然耗时短，但灵敏度很低，漏检率很高。培养方法耗时都非常长，固体培养的结果甚至需要8周的报告时间。这个方法时间过于漫长，其报告结果无法给出肺结核病人的早期诊断依据，耽误肺结核病人的诊治时间。涂片和培养作为结核病防治机构使用最多的方法，两者结果都无法直接区分结核分枝杆菌感染和非结核分枝杆菌感染，在临床上常会导致误诊。据报道，在培养阳性的菌株中，有近20%都是非结核分枝杆菌。临床上通常会对痰涂片阳性结果或者痰培养阳性结果的病人进行抗结核病治疗，抗结核病药物治疗对病人的肝损伤非常严重。对于非结核菌感染的病人被误诊为结核菌感染，给病人的身心带来痛苦之外，不仅延误了病人的治疗时间，也增加病人的治疗负担。</p><p align="justify">自2000年后核酸扩增技术（NAAT）在美国成为TB诊断的一个常规诊断方法，2008年更新的美国CDC指南中指出对于每一个TB疑似患者至少有一个样本应当使用NAAT法检测。SAT是一种结核病NAAT检测新技术，不仅灵敏度和特异性非常高，且能区分结核分枝杆菌和非结核分枝杆菌。另外，SAT方法采用超声波破碎结核菌，操作简单，容易掌握，而且耗时短，最快2小时报告结果。满足临床上对于结核病诊查的快速、准确的要求。</p><p align="justify" class="news004">TB-SAT——准确、快速、鉴别NTM，可用于多种样本类型的结核感染监测</p><p align="justify" class="news004">&nbsp;</p><p align="justify"><span class="news004">· 准确</span> SAT方法具有较高的准确度，大大提高涂阴标本的阳性检出率。</p><p align="justify"><span class="news004">· 快速、简便</span> SAT方法采用新型的超声波破碎结核菌的方法，仅需15分钟就可以完成核酸提取过程，操作流程简单，适合各级结防机构检验人员掌握。最快2小时就可以报告检测结果，快速地向临床提供结核病患者的诊断依据。</p><p align="justify"><span class="news004">· 鉴别NTM</span> 区分结核分枝杆菌和非结核分枝杆菌感染，经过大量的临床特异性数据证明，SAT方法的特异性达到97.85%~100%。SAT可以从疑似结核感染的病例中准确鉴别出结核菌感染病例，帮助临床作出准确的诊断，提高临床诊治水平，减少病人诊治周期和治疗成本。</p><p align="justify"><span class="news004">· 区分死菌活菌</span> 指导医生准确用药，合理使用抗结核药物，减少耐药结核的产生。</p><p align="justify"><span class="news004">· 多样本类型</span> 可应用于痰液、肺泡灌洗液等多种样本类型的检测。</p><p align="justify"><strong>TB-SAT在临床中的应用</strong></p><p align="justify"><span class="news004">应用科室：</span>呼吸科/传染科/感染科/结核科</p><p align="justify"><span class="news004">适应症:</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- 疑似症状患者的（开放性）肺结核感染排查&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- 转诊患者的肺结核感染确认和鉴别诊断&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- 肺结核与呼吸道其他疾病的鉴别诊断&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- 肺结核随访患者的临床治疗效果辅助评估</p><p align="justify" class="news004">TB-SAT诊断结核感染临床应用进展</p><p align="justify">SAT技术的检测靶标和扩增产物均为RNA，由于RNA不稳定，易降解，在实验室污染控制方面与各项DNA分子诊断技术相比，有其独特的优势；SAT技术与目前使用的传统痰涂片抗酸染色检测方法、传统培养法及液体培养法比较，能显著提高结核分枝杆菌的阳性检出率，对早期发现传染性肺结核患者，控制结核病传染源都有重要意义。作为一项成熟的检测技术，TB-SAT目前已成功地应用于上海肺科医院、西安胸科医院、解放军309医院、杭州市红会医院、黑龙江省结核病院等多家知名医院以及卫生部医药卫生科技发展中心的结核快速诊断临床研究课题。</p><p align="justify"><span class="news004">结语</span> 由上海仁度生物研发的TB-SAT用于结核分枝杆菌感染的检测在国内有多年临床运用，取得了良好的临床效果，国内已有实力雄厚的医院均有或准备开展此项检测，并且在结核分枝杆菌研究的国家课题中也已开始运用，现有多篇TB-SAT技术文献发表于国内外包括《Journal of Clinical Microbiology》、《中国防痨杂志》、《中华检验医学杂志》等著名期刊。该公司近期还在研究结核耐药菌及NTM的SAT检测方法，期望能够为我国的结核防治工作作出更多贡献，欲了解更多SAT技术详情可到他们网站查询：<a href="http://www.rdbio.com">www.rdbio.com</a>。</p><p align="justify">随着SAT检测技术在国内的发展，让我们拭目以待，希望此项技术能为国内的结核分枝杆菌诊断带来一场革命，为我国大众健康带来更多福音。</p><p><span class="news004">参考文献</span> 【1】Zhenling Cui et al. Novel Real-Time Simultaneous Amplification and Testing Method To Accurately and Rapidly Detect Mycobacterium tuberculosis Complex Journal of Clinical Microbiology,2012. 【2】崔振玲，胡忠义，《RNA恒温扩增技术快速检测痰标本中结核分枝杆菌的研究》，中华结核和呼吸杂志2011年12月第34卷第12期 【3】倪丽丽，陈晋，《恒温扩增实时荧光检测技术在肺结核诊断中的临床价值》，中华检验医学杂志2012年8月第35卷第8期 【4】沙巍，何娅，肖和平等，《实时荧光核酸恒温放大检测（ＳＡＴ）法对肺结核诊断价值的研究》，中国防痨杂志2012年6月第34卷第6期</p><p align="left" class="news03">&nbsp;</p></div></div>    
                            </div>
        </div>
                        <div class="news-related">
            <h2 class="font-medium">More News</h2>
            <div class="view view-news view-id-news view-display-id-related hlocked view-dom-id-3825fcfa9991a99fa81863a32f683c22">
        
  
  
      <div class="view-content">
      <div class="news-related-items">    <ul class="news-related-item">          <li class="">    <a href="/en/news/qiming-venture-partners%E2%80%99%C2%A0insilico-medicine-successfully-lists-hong-kong-stock-exchange"
       data-node-id="7550">
        <span class="news-type">Portfolio News</span>
<span class="news-title">Qiming Venture Partners’ Insilico Medicine Successfully Lists on Hong Kong Stock Exchange </span>
<span class="news-date font-din"><strong><span class="date-display-single">12/30</span></strong> <span class="date-display-single">2025</span></span>
    </a></li>
          <li class="">    <a href="/en/news/qiming-venture-partners-portfolio-company-weride-completes-dual-primary-listing-hong-kong-stock"
       data-node-id="7517">
        <span class="news-type">Portfolio News</span>
<span class="news-title">Qiming Venture Partners&#039; Portfolio Company WeRide Completes Dual Primary Listing on Hong Kong Stock Exchange </span>
<span class="news-date font-din"><strong><span class="date-display-single">11/06</span></strong> <span class="date-display-single">2025</span></span>
    </a></li>
          <li class="">    <a href="/en/news/longwood-biopharmaceuticals-secures-hundreds-millions-series-b-financing-accelerate-core"
       data-node-id="7437">
        <span class="news-type">Portfolio News</span>
<span class="news-title">Longwood Biopharmaceuticals Secures Hundreds of Millions in Series B+ Financing to Accelerate Core Pipeline Clinical Research and Global Layout </span>
<span class="news-date font-din"><strong><span class="date-display-single">10/29</span></strong> <span class="date-display-single">2025</span></span>
    </a></li>
          <li class="">    <a href="/en/news/qiming-venture-partners-exclusively-leads-makeras-pre-round"
       data-node-id="7426">
        <span class="news-type">Portfolio News</span>
<span class="news-title">Qiming Venture Partners Exclusively Leads Makera&#039;s Pre-A Round </span>
<span class="news-date font-din"><strong><span class="date-display-single">10/17</span></strong> <span class="date-display-single">2025</span></span>
    </a></li>
          <li class="">    <a href="/en/news/qiming-venture-partners-portfolio-company-yunji-technology-successfully-lists-hong-kong-stock"
       data-node-id="7425">
        <span class="news-type">Portfolio News</span>
<span class="news-title">Qiming Venture Partners&#039; Portfolio Company Yunji Technology Successfully Lists on the Hong Kong Stock Exchange </span>
<span class="news-date font-din"><strong><span class="date-display-single">10/16</span></strong> <span class="date-display-single">2025</span></span>
    </a></li>
      </ul></div>    </div>
  
  
  
  
  
  
</div>        </div>
            </div>
</div></div>
            </div>
<div class="footer">
    <div class="w">
                    <div class="footer-right">
                    <div id="block-block-3" class="block block-block">

    
    <p><a class="mail" href="mailto:contactus@qimingvc.com">&nbsp;</a> <a class="linkedin" href="https://www.linkedin.com/company/qiming-venture-partners" target="_blank"><!--<span><img alt="" src="/sites/all/themes/qiming/images/linkedin.jpg" /></span>--></a> <a class="weibo" href="https://twitter.com/QimingVC" style="background-image: url(/sites/default/files/twitter-5.png);"><!--<span><img alt="" src="/sites/all/themes/qiming/images/wb.jpg" /></span>--></a> <a class="wx" href="javascript:;"> <img alt="" src="/sites/default/files/WechatIMG230130.jpeg" /><br />
WeChat</a></p>
</div>
            </div>
                            <div class="footer-t clearfix">
                    <div id="block-block-2" class="block block-block">

    
    <div class="footer-nav">
<ul>
	<li><a href="/en/team">Team</a></li>
	<li><a href="/en/portfolio">Portfolio</a></li>
	<li><a href="/en/newsroom">Newsroom</a></li>
	<li><a href="/en/about">About Us</a></li>
	<li><a href="/en/careers">Careers</a></li>
	<li><a href="/en/contact">Contact Us</a></li>
	<li><a href="/en/legal">Legal</a></li>
	<li style="display:none;"><a href="https://www.qimingvcusa.com/" target="_blank">Qiming US</a></li>
</ul>
</div>
</div>
<div id="block-block-6" class="block block-block">

    
    <div class="footer-contact">
<ul>
	<li>BP Submission: <a href="mailto:BP@qimingvc.com">BP@qimingvc.com</a></li>
	<li>Media Enquiry: <a href="mailto:PR@qimingvc.com">PR@qimingvc.com</a></li>
	<li>Feedback: <a href="mailto:contactus@qimingvc.com">contactus@qimingvc.com</a></li>
</ul>
</div>
</div>
            </div>
                <div class="footer-b font-semibold clearfix">
                <div id="block-block-4" class="block block-block">

    
    <p>©2019 Qiming Weichuang Venture Capital Management (Beijing) Co., Ltd. All Rights Reserved. <a href="/sitemap" style="display: none">网站地图</a> <a href="javascript:;" style="display: none">隐私</a>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;沪ICP备12032307号-1</p>
</div>

        </div>
    </div>
</div>

<div id="layer"></div>
    <div class="pop-nav">
        <!--
            <div class="lang-box">
                            </div>
        -->                                <div id="block-system-main-menu" class="block block-system block-menu">

    
    <ul class="menu clearfix"><li class="first leaf"><a href="/en/team">Team</a></li>
<li class="leaf"><a href="/en/portfolio">Portfolio</a></li>
<li class="leaf"><a href="/en/insights">Insights</a></li>
<li class="leaf"><a href="/en/newsroom">Newsroom</a></li>
<li class="last leaf"><a href="/en/about">About Us</a></li>
</ul></div>
                    <div id="block-menu-block-1" class="block block-menu-block">

    
    <div class="menu-block-wrapper menu-block-1 menu-name-menu-pop-menu parent-mlid-0 menu-level-1">
  <ul class="menu clearfix"><li class="first leaf menu-mlid-779"><a href="/en/careers">Careers</a></li>
<li class="leaf menu-mlid-778"><a href="/en/contact">Contact Us</a></li>
<li class="last leaf menu-mlid-780"><a href="/en/legal">Legal</a></li>
</ul></div>
</div>
        
        <a href="javascript:;" class="pop-close">&nbsp;</a>
    </div>
<!--手机端投资公司页面详情弹框-->
<div class="portfolio-pop" id="portfolioPop">
    <a href="javascript:;" class="close">&nbsp;</a>
    <div class="portfolio-pop-main">
    </div>
</div>      <script type="text/javascript" src="https://www.qimingvc.com/sites/default/files/js/js_YD9ro0PAqY25gGWrTki6TjRUG8TdokmmxjfqpNNfzVU.js"></script>
<script type="text/javascript" src="https://www.qimingvc.com/sites/default/files/js/js_0rg3W8bajVerWxJWxHfplTrhy8SCP6GaFU1_qhf43Os.js"></script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
jQuery.extend(Drupal.settings, {"basePath":"\/","pathPrefix":"en\/","setHasJsCookie":0,"ajaxPageState":{"theme":"qiming","theme_token":"0_SkbyXCWOoP7rFcc34X4SNDI2NiGmpmeUUSddulfqg","js":{"misc\/jquery.js":1,"misc\/jquery-extend-3.4.0.js":1,"misc\/jquery-html-prefilter-3.5.0-backport.js":1,"misc\/jquery.once.js":1,"misc\/drupal.js":1,"sites\/all\/themes\/qiming\/js\/jquery.js":1,"sites\/all\/themes\/qiming\/js\/swiper.min.js":1,"sites\/all\/themes\/qiming\/js\/common.js":1,"sites\/all\/themes\/qiming\/js\/main.js":1},"css":{"modules\/system\/system.base.css":1,"modules\/system\/system.menus.css":1,"modules\/system\/system.messages.css":1,"modules\/system\/system.theme.css":1,"modules\/field\/theme\/field.css":1,"modules\/node\/node.css":1,"modules\/user\/user.css":1,"sites\/all\/modules\/views\/css\/views.css":1,"sites\/all\/modules\/ckeditor\/css\/ckeditor.css":1,"sites\/all\/modules\/media\/modules\/media_wysiwyg\/css\/media_wysiwyg.base.css":1,"sites\/all\/modules\/ctools\/css\/ctools.css":1,"sites\/all\/modules\/panels\/css\/panels.css":1,"modules\/locale\/locale.css":1,"sites\/all\/modules\/date\/date_api\/date.css":1,"sites\/all\/themes\/qiming\/css\/swiper.min.css":1,"sites\/all\/themes\/qiming\/css\/base.css":1,"sites\/all\/themes\/qiming\/css\/index.css":1,"sites\/all\/themes\/qiming\/css\/ie.css":1,"public:\/\/css_injector\/css_injector_2.css":1,"public:\/\/css_injector\/css_injector_3.css":1}},"better_exposed_filters":{"views":{"news":{"displays":{"related":{"filters":[]}}}}}});
//--><!]]>
</script>
      <!--
    <script src="/js/contact.js" type="text/javascript"></script>
  -->        </body>
</html>

